Molecular epidemiology integrates molecular technologies and ideas into epidemiological studies of disease origins and outcomes. The translational goals of such research are to understand a disease sufficiently to enable the development of strategies to reduce the patient population burden. With respect to glioma origin and survival rates for adults, approaches based on molecular epidemiology have been used to classify glial tumors into more homogeneous categories, to study the roles of common genetic polymorphisms, and to identify biomarkers related to developmental or environmental risk factors for gliomas. Because there have been several recent reviews of brain tumor epidemiology and pathogenesis, we refer interested readers to these papers for details. 8, 14, 74,78, 115, 123, 183 The purpose here is to provide the context for molecular epidemiology studies of gliomas, to highlight recent findings, and to suggest promising paths for future research.
er than 45 years at GBM diagnosis survive for 2 years. 28 Furthermore, although survival rates for individuals with GBM have shown no notable improvements in population statistics for more than 30 years, 38 recent clinical trial data on the use of combined radiotherapy and temozolomide found a median survival period of 14.6 months compared with 12 months for patients treated with radiotherapy alone. 154 
GENERAL MOLECULAR PATHOLOGICAL NATURE OF GLIOMAS

Commonly Altered Chromosomal Regions
Classic cytogenetic and array-based comparative genomic hybridization studies of gliomas have identified copy number changes (deletions, amplifications, and gains) in several regions; deletions and loss of heterozygosity in tumors may indicate genes involved in tumor suppression, whereas amplifications and gains may point to genes involved in tumor initiation or progression (for example, oncogenes). The more regularly observed of these changes, which may vary by histological type, as well as some candidate genes in the regions include gains and deletions in 1p (1p36.31-pter, 1p36.22-p36.31, and p34.2-p36.1), gains in 1q32 (RIPK5, MDM4, PIK3C2B, and others), deletion of 4q (NEK1 and NIMA), amplifications and gains in chromosome 7 (7p11.2-p12, EGFR), deletions in chromosome 9 (9p21-p24, CDKN2), deletions in chromosome 10 (10q23, PTEN; 10q25-q26, MGMT), deletions in chromosome 11 (11p [between CDKN1C and RRAS2]), amplifications of 12 (12q13.3-q15, MDM2, CDK4, and many others), loss of 13 (13p11-p13 and 13q14-q34, RB1), loss of 19 (19q13, GLTSCR1, GLTSCR2, LIG1, PSCD2, and numerous others), loss of 22 (the 22q11.21-12.2 region has 28 genes including INI1, known for its involvement in rhabdoid tumors, and q13.1-13.3). These issues are reviewed by Ichimura, et al., 74 and many others. 17, 45, 49, 60, 69, 77, 87, 118, 126, 130, 131, 133, 151, 155, 156 This brief summary demonstrates that although several well-known tumor suppressor genes and oncogenes occur in these regions, many genes in the regions have yet to be identified for their specific relationship to glioma genesis.
Dysregulated Pathways in Astrocytic Gliomas
Classic molecular and cytogenetic studies of tumors as well as the newer array-based assays of comparative genomic hybridization and RNA expression indicate substantial heterogeneity of genes and gene expression within and between histological grades of astrocytic tumors and between different histological types of gliomas. 51, 74, 89, 94, 113, 114, 128 It has become increasingly apparent that such heterogeneity at the cellular level reflects the action of different causal mechanisms in the pathogenesis of the disease. Because astrocytic gliomas compose more than 70% of all adult gliomas, we emphasize pathways known to be important for these tumors and do not provide a comprehensive review here of this rapidly expanding area of research. The phenotype called GBM arises from dysregulation of several different pathways. Dysregulation can occur from a variety of genetic and epigenetic mechanisms, including gene mutation, amplification, deletion, methylation or demethylation, whole or partial chromosome gains or losses, and transcriptional interference. 74, 82, [88] [89] [90] 177 Several interrelated pathways are well established as being dysregulated in GBM and other gliomas. Recurring themes are that these pathways are involved in cell-cycle signaling and control (proliferation and apoptosis), cytoskeleton regulation, transcription, growth signaling, cell adhesion, migration, and cytokine response (Table 1) . 74 
Molecular Pathways to GBM
Progress has been made with respect to elucidating the genetic pathways that lead to GBMs. It is now believed that these tumors arise by two pathways that can be defined in clinical terms: one pathway results from tumor progression from lower-grade astrocytomas ("secondary" GBM) and a second pathway has no clinically evident precursor ("primary" or "de novo" GBM). Interestingly, examination of two molecular aberrations, TP53 mutation and EGFR amplification, has led to their correlation with the type of GBM defined on a clinical basis. 94, 164 Specifically, tumors with TP53 mutations are more likely to be secondary GBMs, arising from lower grade precursors, whereas a de novo GBM is more likely to harbor EGFR amplification. Although this distinction is not absolute and has recently been called into question, 116 it raises the possibility that distinct subtypes of GBM may be similar histologically yet display clinical differences, specifically in response to therapeutic agents. Molecular subtyping is currently not routine but is likely to be of use in the future as an adjunct to histological analysis in the classification of these tumors.
Population Studies of Tumor Markers in Astrocytic Gliomas
To date only two studies have presented data on genetic and molecular tumor markers for relatively large numbers of population-based glioma cases. 114, 177 Although in each study five or six tumor markers were assessed, only two (EGFR amplification and TP53 mutation) were measured in both studies. Interestingly, the percentage of GBMs with EGFR amplification was identical in the two studies (36% of 371 de novo GBMs from Zurich and 36% of 386 GBMs from the San Francisco Bay area). The percentage of tumors with a TP53 mutation varied from 28% of 386 GBMs from Zurich to only 15% of 409 GBMs from San Francisco; percentages in clinical series have ranged from 20 to 30%. 81 Despite some inconsistencies, these findings support the hypothesis, proposed in smaller clinical series, that astrocytic tumors may arise through different pathways and may reflect the action of different causal mechanisms. To summarize current findings for astrocytic tumors, TP53 tumor mutations are associated with a younger age at diagnosis and are more common in lower-grade tumors and in GBMs arising from them; 82, 89, 114, 127, 177 TP53 tumor mutations are more common in non-Caucasians, whereas tumors overexpressing EGFR or containing p16 deletions are more common in Caucasians; 106, 177 MGMT 84Phe carriers are overrepresented among GBM cases in which tumors do not overexpress TP53 protein; 177 and the GSTT1 constitutive deletion is more common among GBM cases in which the tumor displays the TP53 mutation. 181 M. Wrensch, et al.
SURVIVAL RATES AND PROGNOSIS FOR PATIENTS WITH GLIOMAS
Information on survival rates and prognosis for patients with gliomas comes from clinical trials and population registry data. Studies from the Radiation Therapy Oncology Group and other clinical trial groups provide useful information on prognostic factors from cases whose pathological features have been centrally reviewed and for patients who qualify for and are treated in clinical trials. Because the majority of patients do not enter clinical trials, however, the results might not be applicable to or representative of the general population of patients with gliomas. Survival rate estimates based on population registry data can represent the full spectrum of patients in whom gliomas are diagnosed, yet pathological diagnoses are subject to considerable variability depending on numerous factors, including the pathologist's neuropathological training 1 and the time and place the diagnosis was made. 35, 83 Also, population registries do not generally have treatment data as extensive as that available from clinical trials.
Histological type and grade of tumor, patient age, extent of lesion resection, tumor location, whether the patient undergoes radiation therapy, and some chemotherapy protocols have been consistently and convincingly linked to survival in both population registry and clinical trial data. 29, 36, 38, 39, 66, 93, 96, 141, 142 The Karnofsky Performance Scale score at diagnosis and other measures of mental and physical functionality also predict survival for patients with GBMs and anaplastic astrocytomas enrolled in the Radiation Therapy Oncology Group and other multiinstitutional clinical trials. 36, 93, 141 In addition to these factors, investigators are currently trying to identify and understand tumor markers or patient characteristics that might influence survival or response to treatment; 10, 25, 51, 53, 92, 97, 113, 117, 125, 137, 144, 146, 158, 170, 189 specific examples are presented later in this paper. A key unsolved problem in neurooncology is the strong and consistent inverse relationship of age to survival. The reasons, whether they pertain to properties related to the tumor or the host, are not well understood. The response of tumors to radiation has been reported to be poorer in older patients. 5 In this regard, one contributing factor may be related to different frequencies of molecular or chromosomal aberrations among tumors in older patients compared with those in younger patients (a topic that will be discussed subsequently). One difficulty in identifying prognostic factors in rapidly fatal gliomas such as GBMs may be related to the narrow range of survival time experienced by the vast majority of patients. One method to address this limitation is to compare tumors from rare long-term survivors with those from typical GBM survivors. Studies performed at the University of Texas M. D. Anderson Cancer Center, using both a candidate gene approach 23 and a genome-wide screen, 22 have indicated that differences exist between tumors obtained in long-term survivors and those obtained from typical GBM survivors. 22 Although such studies may not be as easily extended to clinical use as prognostic markers, they point to aberrations that may be responsible for the nearly uniformly poor prognosis for patients with GBM.
Studies of Tumor Markers in Relation to Survival
Combined losses of 1p and 19q in oligodendroglial tumors are well-established favorable prognostic indicators. 25, 49, 50, 61, 70, 76, 87, 148, 149, 161 In astrocytic tumors, amplification/ overexpression of EGFR is more common in older patients, especially those with anaplastic astrocytoma; 177 this amplification/overexpression may also contribute to resistance to therapeutic modalities. 6, 191 Although EGFR amplification is more common in tumors from older individuals, it is not exclusive to that age group and may be associated with poor survival rates in younger (Ͻ 55-60 years of age) adults with GBM. 146, 150 A subset of tumors with EGFR amplification demonstrates an additional change in the EGFR gene resulting from an internal rearrangement called EGFRvIII. Although the results of large studies have yet to be reported, the presence of the EGFRvIII allele may also be a negative prognostic factor. 48, 64 Data from a recent large prospective trial of patients with newly diagnosed GBMs have indicated that methylation of the MGMT promoter in GBM tumor samples was a marker of improved outcome, as measured by the 2-year survival rate. 154 Interestingly, MGMT methylation appeared to be much more strongly associated with survival among patients who received frontline temozolomide than among those who did not, 63 raising the possibility that MGMT methylation may be a predictive marker of response to this alkylating agent.
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Insights From Expression Array Studies of Gliomas
In two recent studies the investigators assessed the prognosis for patients with gliomas from expression profiles alone 51 or in conjunction with comparative genomic hybridization. 113 Although some a priori candidate genes were validated, it was important that many new genes whose expression had not been previously linked to patients surviving gliomas were also identified, and abnormal expression in certain classes of genes predicted survival. For example, best, intermediate, and worst survival times were associated with the abnormal expression of neurogenesis genes, cell proliferation and mitosis genes, and extracellular and extracellular matrix genes, respectively. 51 Other important findings include the following: 1) loss of chromosome 10 was accompanied by gene expression changes across the genome; and 2) the copy number loss of chromosome 10 and gains of chromosomes 7, 19, and 20 were highly correlated with one another. 113 These findings, although compelling, are nevertheless preliminary because of the relatively small sample sizes typical of expression array studies. Candidate markers identified in such genome-wide screens, however, represent promising leads for possible validation in larger studies. A recent array study of oligodendroglioma and oligoastrocytoma found that a tumor gain of 8q may be a negative prognostic factor. 87 
Constitutive Genetic Influences on Prognosis and Survival for Patients With Gliomas
It is being increasingly demonstrated that common gene polymorphisms influence response to cancer therapies or otherwise influence prognosis and survival (recent reviews on this topic include papers by Loktionov 98 and Nagasubramanian, et al. 109 ). Survival after a diagnosis of glioma has been associated with polymorphisms in EGF, GSTP1, and GSTM1; HLA A*32 and B*55; and GLTSCR1 S397S and ERCC2 D711D. 10, 117, 158, 187 Because none of these findings has yet been replicated, cautious interpretation is advised. Potentially relevant associations between polymorphisms in genes and treatment response or survival for other cancer sites include the following: IL6 and aggressive breast cancer and ovarian cancer, ATM and radiosensitivity of breast cancer patients, TGFB1 and breast cancer survival, TNF and myeloma relapse, GSTP1 and myeloma outcomes, MDR1 and acute leukemia survival, FGFR4 and soft-tissue sarcoma survival, TYMS and colorectal cancer survival, CDKN2A and bladder cancer survival, and TP53 and lung cancer prognosis. 4, 31, 37, 42, 62, 67, 73, 75, 108, 112, 135, 143, 167, 168 One proposed mechanism is that TP53 variants alter function and the response of tumor cells to chemotherapeutic agents. 157 The limited studies that have been performed to date have provided several potentially fruitful areas of discovery regarding genetic variation in relation to survival rates for patients with gliomas (for example, signaling pathways for growth factors, cell cycle regulators, modifiers of drug metabolism, and radiotherapy and the immune response).
ENVIRONMENTAL, DEVELOPMENTAL, AND GENETIC RISK FACTORS FOR GLIOMAS
The only exogenous environmental cause of gliomas that has been unequivocally established is high-dose therapeutic radiation; high-dose chemotherapy for other cancers is a strong possibility as well. 43, 115, 183 Genetic factors influence risk from these exposures; Relling, et al., 132 showed that among children treated with cranial radiotherapy and intensive antimetabolite therapy for acute lymphocytic leukemia, those with germline polymorphisms leading to low or absent thiopurine methyltransferase activity were significantly more likely than those without such polymorphisms to develop brain cancer.
Although abundant data obtained in animal and other studies support the biological plausibility of neurocarcinogenecity of endogenous and exogenous chemicals (for example, N-nitroso compounds, reactive oxygen and nitrogen species, several industrially used chemicals, and polycyclic aromatic hydrocarbons) to which people are exposed through their essential cellular metabolism, diet, occupation, and personal habits, inconsistent or often null findings from human studies result from a variety of issues. 3, 11, 12, 20, 27, 30, [32] [33] [34] 58, 59, 68, 71, 80, 91, 95, 100, 105, 111, 115, 120, 124, 159, 171, 183, 190 These include small study sample sizes, chance reporting of false-positive results, imprecise exposure measures (from proxy reporting and exposure history recall issues), inherited or developmental variation in metabolic and repair pathways, unaccounted for protective exposures, differential diffusion of chemicals across the blood-brain barrier, differentially expressed metabolic and repair pathways in the brain, and disease heterogeneity. 55, 78, 115, 145, 169 Progress has been made in understanding environmental contributors to other cancers by joint consideration of inherited variation in detoxification, metabolism, or repair and histological or molecular tumor subtypes, such as TP53 mutations. Two classic examples include the demonstration that specific TP53 mutations in hepatocellular carcinoma occurred exclusively in carriers of variants in epoxide hydrolase and glutathione transferase mu 103 and the finding that TP53 mutations in patients with lung cancer were more common in heavy smokers compared with nonsmokers and that homozygous carriers of the glutathione transferase mu deletion were more likely to have transversion mutations in TP53. 134 More recent examples have shown interactions between a vitamin D receptor polymorphism and dietary calcium and vitamin D intake in evaluating the risk of colorectal adenoma, 18, 86 interactions of a detoxification gene variation with different environmental exposures in gauging lung cancer risk, 72, 104, 147 and different polymorphisms and parental characteristics associated with varying risks of molecularly defined subgroups of childhood leukemia. 173, 176 Because only a small proportion of gliomas are likely to be caused by the effects of inherited rare mutations or highdose radiation, researchers have focused on polymorphisms in genes that might influence susceptibility to brain tumors in concert with environmental exposures.
Polymorphisms in Carcinogen Metabolism and Gliomas
Glutathione S-transferases and CYPs, as part of the Phase 1 and 2 detoxification process, are involved in the metabolism of many electrophilic compounds, including carcinogens, mutagens, cytotoxic drugs, and metabolites, as well as in the detoxification of products of reactive oxidation. 26 181 the GSTM1 deletion was less common (p = 0.03) and GSTP1 A114V V-carriers were more common than expected (p = 0.06) among oligodendroglioma cases. 41 The significant multiplicative effects of GSTP1 I105V and CYP2E1 RsaI variants 41 suggest that gene interactions may be important.
Gliomas and DNA Repair Gene Polymorphisms
The study of the inherited variation in DNA repair involves another category of genes that have been extensively investigated with respect to cancer because of the importance of DNA repair in maintaining genomic integrity. 9, 107, 179 In 2002, Goode and colleagues 56 reviewed 30 studies reporting on DNA repair polymorphisms in adult gliomas and cancer of the bladder, breast, lung, skin, prostate, head and neck, stomach, and esophagus; the number of studies published has more than quadrupled in the past 3 years. Gliomas and glioma subtypes have been significantly associated with variants in ERCC1, ERCC2, the nearby gene GLTSCR1 (glioma tumor suppressor candidate of unknown function), PRKDC (also known as XRCC7), and MGMT, 166, 177, 180, 187 but too few studies have been performed to assess consistency. The complexity of the DNA repair pathway is increasingly being revealed, with 130 known genes involved in base excision repair, direct reversal of damage, mismatch repair, nucleotide excision repair, homologous recombination, nonhomologous end joining, sanitization of nucleotide pools, activity of DNA polymerases, editing and processing of nucleases, and postreplicative repair; genes associated with sensitivity to DNA damaging agents; and others suspected of influencing DNA repair functioning are also involved.
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Studies focusing on constellations of DNA repair variants involved in these pathways might help elucidate their roles in gliomagenesis and progression.
Gliomas and Polymorphisms in Cell Cycle Regulation
Dysregulation of the cell cycle (control of proliferation and apoptosis) is a hallmark of most gliomas reviewed by Ichimura, et al., 74 and MDM2 is a key molecule in maintaining the fidelity of this process. In one study, 13 the G variant of SNP309 in the MDM2 promoter led to higher expression of MDM2, with concomitant reduced expression of TP53, and was found to be significantly associated with an earlier patient age at tumor development and multiple tumor sites in patients with Li-Fraumeni syndrome, in whom brain tumors are one component.
Infections and Immunological Risk Factors for Gliomas
Among the most intriguing and consistent findings of the past decade are statistically significant inverse associations between gliomas that develop during adulthood and histories of allergies, chicken pox, and anti-varicella-zostervirus immunoglobulins G and E. 19, 138, 140, 174, 175, 182, [184] [185] [186] To address lingering doubts that the negative association of gliomas with an allergy history might result from recall issues, Schwartzbaum and colleagues 139 recently demonstrated that single nucleotide polymorphisms in genes related to asthma are also related to GBM, but in the opposite direction to their association with asthma. To clarify the observed inverse associations of gliomas with asthma, Schwartzbaum, et al., 139 studied the associations of GBMs with polymorphisms known to be strongly associated with asthma. They examined five single nucleotide polymorphisms in three genes, IL4RA, IL13, and ADAM33; IL4RA T478C TC, CC and A551G AG, AA were significantly positively associated with GBMs (OR 1.64, 95% CI 1.05-2.55 and OR 1.61, 95% CI 1.05-2.47, respectively, whereas IL13 C1112T CT, TT was inversely associated with GBMs (OR 0.56, 95% CI 0.33-0.96). The polymorphism-GBM associations are in the opposite direction of the polymorphism-asthma associations and because the investigators used germline polymorphisms as biomarkers of the susceptibility to asthma and allergies, the results cannot be attributed to either a recall bias or to the effects of GBMs on the immune system. These findings may validate the association between selfreported allergic conditions and GBMs; however, IL-13 or its shared receptor with IL-4, IL-4RA, may play independent roles in allergic conditions and GBMs. Alternatively, some aspect of allergic conditions themselves may reduce the risk of the development of a GBM or glioma. In either case, these results for allergic conditions and viral infections are consistent with our hypothesis that it is the specific nature of the immune system's response to antigens and not exposure to the antigen per se that is responsible for the inverse associations with gliomas, because there is nearly universal exposure to antigens for both varicella-zostervirus and allergies to pollen, food, and so forth.
Tang and colleagues 158 demonstrated that GBM is positively associated with human leukocyte antigen genotypes/ haplotypes B*13 and B*07-Cw*07 (p = 0.01 and p Ͻ 0.001, respectively) and is inversely associated with Cw*01 (p = 0.05). Interestingly, if confirmed, these results may partially explain the higher incidence of GBM in Caucasians because B*07 and B*07-Cw*07 are much more common in Caucasians.
A variety of other viral infections (simian virus 40, JC, BK, other papovaviruses, adenoviruses, retroviruses, the herpesviruses cytomegalovirus and HHV-6, and influenza) and parasitic infections (Toxoplasma gondii) have been investigated in relation to gliomagenesis in experimental studies on animals and in limited epidemiological studies, but conclusions regarding the role (if any) of these infectious agents in human gliomas have remained elusive.
2,78,183
Genetic Syndromes, Familial Aggregation, Linkage, and Mutagen Sensitivity
In addition to results from genetic polymorphism studies, evidence suggesting genetic susceptibility to brain cancer comes from studies of genetic syndromes, familial aggregation, linkage, and mutagen sensitivity. Although the handful of genetic syndromes (caused by inherited rare mutations) associated with increased risk of brain tumors (for a review see other studies 14, 46, 74 ) account for a small proportion of cases, they provide an important starting point for identifying candidate genes and pathways that could be involved in gliomagenesis. 14, 46, 74 Syndromes that include gliomas or medulloblastomas (with gene names and chromosome location) are neurofibromatosis Types 1 and 2 (NF1, 17q11; NF2, 22q12) , tuber-
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Molecular epidemiology of gliomas in adults ous sclerosis (TSC1, 9q34; TSC2, 16p13), retinoblastoma (RB1, 13q14), Li-Fraumeni syndrome (TP53, 17p13), and Turcot syndrome and multiple hamartoma (APC, 5q21; hMLH1, 3p21.3; hMSH2, 2p22-21; PMS2, 7p22; and PTEN, 10q23.3). The roles of more common variants in many of these genes (and related pathways) in sporadic gliomas are unknown.
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Demonstration of familial aggregation does not prove a genetic origin, but it is often among the first indicators that genetic susceptibility may play a part in the pathogenesis of a complex disease. Relative risks of brain tumors among family members of patients who harbor them have ranged from 1 to 10; in large, well-conducted studies, familial glioma risks are approximately twofold, similar in magnitude to the familial association involved in breast cancer and other cancers for which susceptibility genes have been identified (for a review see Bondy, et al., 14 and other studies 65, 101, 182 ). The pattern of brain tumor occurrence in families has been attributed to environmental causes in one study 57 and to multifactorial causes, polygenic causes, and autosomal recessive inheritance in others.
14,40, 102 Paunu, et al., 119 recently published evidence of a statistically significant linkage to 15q23-q26.3 in 15 Finnish families with multiple cases of glioma (after stringent control for multiple testing, p = 0.03).
Gamma radiation-induced mutagen sensitivity is more commonly found in peripheral lymphocytes in glioma cases than in control cases, 15, 16 and it has been suggested that such a mutagen sensitivity is at least partly attributable to inherited variation in capacity to repair radiation damage.
FUTURE STUDIES IN THE MOLECULAR EPIDEMIOLOGY OF GLIOMAS
Suspected and novel inherited variations in glioma susceptibility and prognosis are likely to be confirmed and identified through multidisciplinary studies involving pathologists, geneticists, epidemiologists, functional genomicists, bioinformaticians, biostatisticians, immunobiologists, and clinicians. These studies will require integration of the following: 1) traditional and molecular pathological analysis involving cytogenetic and epigenetic classifications of tumors to reduce and refine glioma subgroups; 2) new genomic technologies and bioinformatic/biostatistical tools with which to interrogate and explore candidate genes, regions, and pathways and to enhance new discoveries; 3) high-quality population resources for causal studies to aid in the selection of cases and controls with well-documented familial and demographic data as well as environmental exposure and personal medical history; and 4) case groups with clearly defined treatment histories for prognostic studies. We hypothesize that demographic, environmental, and immunological factors are likely to influence the susceptibility of patients and disease prognosis, and that different constellations of factors may be involved with different histological and molecular subtypes of glioma.
This brief summary of published case-control studies of polymorphisms involving glioma status and prognosis illustrates several important and widespread problems in current research into the association between genes and diseases, including the paucity of studies assessing consistency for many reported associations, the reporting of falsepositive results, and the lack of consideration of functional significance of the polymorphisms studied. 7, 24, 129, 165, 172 Although the most likely explanation of discrepant results among studies is the chance reporting of positive findings in small studies, it is also possible that discrepancies derive from different effects in different populations arising from different exposure and developmental experiences and/or disease heterogeneity. Lack of information on the functional relevance of polymorphisms can also limit reasonable inferences. Future studies will need to include replication or use other means to reduce reporting of false positives.
Different study designs are encouraged because no ideal design is available for the discovery of genetic and environmental associations regarding heterogeneous and relatively rare diseases such as gliomas. Both familial linkage studies and case-control studies may prove helpful in discovering genes associated with glioma susceptibility. For adequate sample sizes and expertise, consortia will be essential for familial linkage studies, studies of gene-environment interactions with even a relatively common glioma subtype such as GBM, and basic epidemiological studies of less common subtypes such as oligodendroglial tumors and other lowgrade glial tumors. The Brain Tumor Epidemiology Consortium (an international group of brain tumor researchers) already has several initiatives in process in these and other areas of brain tumor research.
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SUMMARY
The reasons for variations in glioma incidence according to time of diagnosis, sex, age, ancestry/ethnicity, and geography are poorly understood, as are factors affecting prognosis. There are few established risk factors for gliomas; ionizing radiation and rare mutations in highly penetrant genes associated with certain diseases and syndromes can only be cited to explain relatively few cases. Both familial aggregation of gliomas and the inverse association of allergies and immune-related conditions with gliomas have been shown consistently, but the explanations for these associations are inadequately developed or unknown. Ongoing research on gliomas focuses on classifying homogeneous groups of tumors on the basis of molecular markers and identifying genetic polymorphisms that, in conjunction with developmental experiences and environmental exposures, may increase brain tumor risk. Rather than examine individual genetic polymorphisms in isolation, new research focuses on genetic polymorphisms in pathways involved in carcinogenesis. Related pathways are also studied simultaneously so that confounding by genes with similar functions can be avoided. Large sample sizes are required for such studies, and these large studies will avoid false-positive findings and permit examination of the modifying effects of polymorphisms on environmental exposures, as well as of the potential for interaction between germline mutations and sporadic tumor mutations. Khoury and colleagues 85 recently argued for the importance of genomic studies of diseases with known strong environmental contributors by stating, because almost all human diseases result from interactions between genetic variants and the environment, suggesting that genomic research will not contribute to preventing conditions with known environmental risk factors could perpetuate the false competition between nature and nurture.
For diseases such as gliomas, for which most cases have M. Wrensch, et al. yet to be linked to either an environmental or a genetic cause, the greatest potential for discovery may lie in genomic studies in conjunction with continued evaluation of environmental and developmental factors.
Some limited success has been achieved in advancing the treatment of gliomas (as in the case of oligodendrogliomas), but improving the survival rates for patients harboring astrocytic tumors will probably require many randomized clinical trials of novel treatment strategies. In conclusion, most gliomas have extremely poor prognoses and we have limited knowledge of their causes, how to treat them, and other factors that determine prognoses. Thus, there is a great need for large, well-designed epidemiological studies of potential genetic and environmental risk factors and for randomized controlled trials of prognostic factors and treatment strategies for gliomas. 
